Biogen Halts Development of Tysabri for Acute Ischemic Stroke after Phase IIb Failure

Biogen said today it will scrap development of Tysabri ® (natalizumab) for a new indication of acute ischemic stroke (AIS) after the marketed drug failed a Phase IIb trial.Tysabri missed its primary and secondary efficacy endpoints in the Phase IIb ACTION 2 study, Biogen said.Biogen did not detail those results, saying that detailed findings from ACTION 2 would be presented at an unspecified “future scientific forum.”“While we are disappointed with the ACTION 2 study result